SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115.
  • 2
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-816.
  • 3
    Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42: 711-723.
  • 4
    McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M, et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Meth Med Res 2009; 18: 271-283.
  • 5
    McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Hayes P, Dillon JF, et al. Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006. Epidemiol Infect 2011; 139: 344-353.
  • 6
    Joint Formulary Committee. London: British Medical Association and Royal Pharamceutical Society of Great Britain. British National Formulary; 9AD. No. 58.
  • 7
    Tine F, Graviano D, Giannuoli G, Madonia S, Malizia G, Patti S, et al. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. Pharmacoepidemiol Drug Saf. 2010; 19: 1113-1123.
  • 8
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 9
    Hadziyannis SJ, Sette H,Jr. Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
  • 10
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 11
    Piai G, Scalice E, Focareta R, Terracciano F, de Filippo FR, Forte G, et al. From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. Dig Dis Sci 2006; 51: 1619-1626.
  • 12
    McLeod A, Hutchinson S, Goldberg D. Surveillance of known hepatitis C antibody positive cases in Scotland: results to 30 June 2010. HPS Weekly Report 2010; 44: 429-432.
  • 13
    Cheung RC. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000; 95: 740-747.
    Direct Link:
  • 14
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
  • 15
    Manesis EK, Papatheodoridis GV, Touloumi G, Karafoulidou A, Ketikoglou J, Kitis GE, et al. Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Aliment Pharmacol Ther 2009; 29: 1121-1130.
  • 16
    Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288.
  • 17
    Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol; 2011; 9: 509-516.
  • 18
    Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.
  • 19
    Hay G, Gannon M, Casey J, McKeganey N. Estimating the national and local prevalence of problem drug misuse in Scotland. 2009. Available from: http://www.drugmisuse.isdscotland.org/publications/abstracts/ prevalence2009.htm. Accessed August 2011.
  • 20
    Amin J, Law MG, Micallef J, Jauncey M, Van Beek I, Kaldor JM, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect 2007; 135: 144-150.
  • 21
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
  • 22
    Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S. Risk of hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int J Drug Policy 2011; 22: 102-108.
  • 23
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
  • 24
    Management of hepatitis C. Scottish intercollegiate guidelines network: December 2006. Available at: http://www.sign.ac.uk/pdf/sign92.pdf. Accessed August 2011.
  • 25
    Bate JP, Colman AJ, Frost PJ, Shaw DR, Harley HA. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 2010; 25: 1276-1280.